|
Session 103
Poster Abstracts
Clinical Pharmacology in Adults and Children: Issues of Relevance for Developing Countries
Monday, 1 - 4 pm
Poster Hall |
575
 |
Effect of Rifampin on Pharmacokinetics and Safety of Twice-daily Atazanavir: ACTG Protocol A5213
Edward Acosta*1, M Kendall2, J Gerber3, C Suckow4, S Koletar5, A Zolopa6, L Laughlin5, S Agarwala7, M Child7, D Haas8, and for the A5213 Study Team
1Univ of Alabama at Birmingham, US; 2Statistical & Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of Colorado Hlth Sci Ctr, Denver, US; 4Frontier Sci & Tech Res Fndn, Amherst, NY, US; 5Ohio State Univ, Columbus, US; 6Stanford Univ, CA, US; 7Bristol-Myers Squibb, Princeton, NJ, US; and 8Vanderbilt Univ, Nashville, TN, US |
| 576 |
Pharmacokinetics and 12 Weeks Efficacy of Nevirapine, 400 mg vs 600 mg per day in HIV-infected Patients with Active TB Receiving Rifampicin: A Multicenter Study
Anchalee Avihingsanon*1, W Manosuthi2, P Kantipong3, C Chuchotaworn4, S Moolphate5, N Yamada5, H Yanai5, P Phanuphak1, D Burger6, and K Ruxrungtham7
1HIV Netherlands Australia Thailand (HIV-NAT) Res Collaboration, Thai Red Cross AIDS Res Ctr, Bangkok; 2Bamrasnaradura Inst, Nonthaburi, Thailand; 3Chiang Rai Hosp, Thailand; 4Chest Disease Inst, Nonthaburi, Thailand; 5TB/HIV Res Project, Res Inst of Tuberculosis-Japan Anti-TB Assn, Chaing Rai, Thailand; 6Radboud Univ Med Ctr, Nijmegen, The Netherlands; and 7Faculty of Med, Chulalongkorn Univ, Bangkok, Thailand |
| 577 |
Drug Interaction between Antimalarial Drugs and Efavirenz
Polina German*1, B Greenhouse1, C Coates1, G Dorsey1, P Rosenthal1, E Charlebois1, N Lindegardh2,3, N Lindegardh2,3, D Havlir1, and F Aweeka1
1Univ of California, San Francisco, US; 2Mahidol Univ, Bangkok, Thailand; and 3Ctr for Tropical Med, Univ of Oxford, UK |
| 578 |
Pharmacokinetics and Pharmacodynamics of a Double-boosted PI Regimen of Saquinavir and Lopinavir/Ritonavir in Treatment-naive HIV-1-infected Adults
Jasper van der Lugt*1,2, Jasper van der Lugt*1,2, S Autar1,2, S Autar1,2, S Ubolyam1, D Cooper1,3, D Cooper1,3, J Lange1,2,4, J Lange1,2,4, J Lange1,2,4, P Phanuphak1,5, P Phanuphak1,5, D Burger6, E Fernandez Garcia2, F Wit2,4, F Wit2,4, K Ruxrungtham1,5, and K Ruxrungtham1,5
1HIV Netherlands Australia Thailand (HIV-NAT) Res Collaboration, Thai Red Cross AIDS Res Ctr, Bangkok; 2Intl Antiviral Therapy Evaluation Ctr, Amsterdam, The Netherlands; 3Natl Ctr for HIV Epidemiology and Clin Res, Univ of New South Wales, Australia; 4Academic Med Ctr, Univ of Amsterdam, The Netherlands; 5Faculty of Med, Chulalongkorn Univ, Bangkok, Thailand; and 6Radboud Univ Med Ctr, Nijmegen, The Netherlands |
| 579 |
Reduced Lopinavir Exposure during Pregnancy: A Case Control Study
Gilles Peytavin*1, S Pierre-François2, B Cassard1, P de Truchis3, C Winter4, B Visseaux1, F Damond1, R Tubiana5, L Mandelbrot6, and S Matheron1
1Hosp Bichat-Claude Bernard, Paris, France; 2Zobda Quitman Hosp, Fort de France, France; 3Hosp Raymond Poincare, Garches, France; 4Hosp Montreuil, France; 5Hosp Pitie-Salpetriere, Paris, France; and 6Hosp L Mourier, Colombes, France |
580
|
Pharmacokinetics of Nevirapine, Stavudine, and Lamivudine in HIV-infected Children in Zambia Treated with Pediatric Fixed-dose Combination Tablets
Desiré Kabamba*1, R L'homme2,3, R L'homme2,3, F Ewings4, V Mulenga1, C Kankasa1, M Thomason4, S Walker4, C Chintu1, D Burger2,3, D Burger2,3, D Gibb4, and The CHAPAS study group
1Univ Teaching Hosp, Lusaka, Zambia; 2Radboud Univ Med Ctr, Nijmegen, The Netherlands; 3Nijmegen Univ Ctr for Infectious Diseases, The Netherlands; and 4Med Res Council Clin Trials Unit, London, UK |
|
